Small Animal Internal Medicine

Research Abstract

EN04 - Comparison of Pharmacodynamics Between Insulin Degludec and Insulin Glargine 300 U/mL in Healthy Cats

Thursday, June 14
11:00 AM - 11:15 AM
Location: WSCC 4C-3

Sponsored By 

Insulin glargine 300 U/ml (Toujeo®) and insulin degludec (Tresiba®) are synthetic insulin analogs that are used in people as basal insulin. Toujeo® is more predictable and longer-acting compared to glargine 100 U/ml (Lantus®) in people. The duration of action of Tresiba® is over 40 hours which allows a flexible daily schedule of administration.


We hypothesized that Tresiba® would have longer duration of action compared to Toujeo® in healthy cats. Six healthy purpose-bred cats, each received 0.4 U/kg SQ injections of Tresiba® and Toujeo® on two different days, > 1 week apart. Blood glucose (BG) was measured every 5 min and glucose was administered intravenously at a variable rate with the goal of maintaining BG = 85 mg/dL (“isoglycemic clamp”). Glucose infusion rate was used as a measure of exogenous insulin action. The Shapiro-Wilk test was used to assess normality and normally distributed parameters were compared using paired t-tests.


Onset of action (TOA) was similar (79 ± 27 min for Toujeo®, 60 ± 21 min for Tresiba®, P = 0.3) but the end of action (TEA) and duration of action (TDUR = TEA-TOA) were longer for Toujeo® vs. Tresiba® (TDUR = 828 ± 130 min vs. 620 ± 148 min, respectively, P = 0.04; TEA = 907 ± 135 min vs. 679 ± 127 min, respectively, P = 0.03). There were no other significant differences between the two formulations.


Based on these preliminary data, Toujeo® is longer-acting and therefore better suited than Tresiba® as a once-daily insulin formulation in cats.

Chen Gilor, DVM, PhD, DACVIM

Associate Professor
UC Davis

Dr. Gilor received his DVM (1997) from the Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel. After working in private practice in Israel and New York, he completed a rotating internship in at the Animal Medical Center in New York (2005) followed by a residency in Small Animal Medicine (2008) and a PhD (2010) in the College of Veterinary Medicine, University of Illinois at Urbana-Champaign. Dr. Gilor served two years as an internal medicine consultant for Idexx Laboratories in the UK, and then four years as an Assistant Professor of Small Animal Medicine (2012-2016) at The Ohio State University. Dr. Gilor is an Assistant Professor of Small Animal Internal Medicine at the University of California, Davis. He is a Diplomate of the American College of Veterinary Internal Medicine-Small Animal Internal Medicine.

Presentation(s):

Send Email for Chen Gilor


Assets

EN04 - Comparison of Pharmacodynamics Between Insulin Degludec and Insulin Glargine 300 U/mL in Healthy Cats

Handout

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Comparison of Pharmacodynamics Between Insulin Degludec and Insulin Glargine 300 U/mL in Healthy Cats